Oncotarget

Research Papers:

Identification and preclinical evaluation of the small molecule, NSC745887, for treating glioblastomas via suppressing DcR3-associated signaling pathways

Li-Yun Fann, Ying Chen, Da-Chen Chu, Shao-Ju Weng, Heng-Cheng Chu, Alexander T.H. Wu, Jiann-Fong Lee, Ahmed Atef Ahmed Ali, Tsung-Chih Chen, Hsu-Shan Huang and Kuo-Hsing Ma _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2018; 9:11922-11937. https://doi.org/10.18632/oncotarget.23714

Metrics: PDF 1546 views  |   HTML 2268 views  |   ?  


Abstract

Li-Yun Fann1,2,6, Ying Chen1,3, Da-Chen Chu2, Shao-Ju Weng3, Heng-Cheng Chu4, Alexander T.H. Wu5, Jiann-Fong Lee6, Ahmed Atef Ahmed Ali6, Tsung-Chih Chen6, Hsu-Shan Huang1,3,6 and Kuo-Hsing Ma1,3

1Graduate Institute of Medical Sciences, National Defense Medical Center, Taipei, Taiwan, ROC

2Department of Nursing and Department of Neurosurgery, Taipei City Hospital, Taipei, Taiwan, ROC

3Department of Biology and Anatomy, National Defense Medical Center, Taipei, Taiwan, ROC

4Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan, ROC

5The PhD Program for Translational Medicine, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan, ROC

6Graduate Institute for Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan, ROC

Correspondence to:

Kuo-Hsing Ma, email: [email protected]

Hsu-Shan Huang, email: [email protected]

Keywords: Naphtho [2,3-f]quinoxaline-7,12-dione; decoy receptor 3 (DcR3); [18F]-FDG; animal-PET

Received: July 19, 2017     Accepted: December 11, 2017     Published: December 27, 2017

ABSTRACT

The small-molecule naphtha [2,3-f]quinoxaline-7,12-dione (NSC745887) can effectively inhibit the proliferation of various cancers by trapping DNA-topoisomerase cleavage. The aim of this study was to elucidate cellular responses of NSC745887 in human glioblastoma multiforme (GBM, U118MG and U87MG cells) and investigate the underlying molecular mechanisms. NSC745887 reduced the cell survival rate and increased the sub-G1 population in dose- and time-dependent manners in GBM cells. Moreover, NSC745887 increased expression of γH2AX and caused DNA fragmentation leading to DNA damage. Furthermore, Annexin V/propidium iodide and Br-dTP staining showed the apoptotic effect of NSC745887 in GBM cells. DNA repair proteins of ataxia-telangiectasia mutated (ATM), ATM and Rad3-related, and decoy receptor 3 also decreased with NSC745887 treatment. In addition, NSC745887 caused apoptosis by the caspase-8/9-caspase-3-poly(ADP-ribose) polymerase cascade. An in vivo study indicated that NSC745887 suppressed the [18F]-FDG-specific uptake value in brain tumors. Histological staining also indicated a decrease in Ki-67 and increases in γH2AX and cleaved caspase-3 in the brain tumor area. These data provide preclinical evidence for NSC745887 as a potential new small molecule drug for managing glioblastomas.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 23714